Dominique Figarella-Branger mostly deals with Pathology, Internal medicine, Glioma, Surgery and Oncology. Dominique Figarella-Branger studies Pathology, focusing on Immunohistochemistry in particular. Dominique Figarella-Branger combines subjects such as Endocrinology and Genotype with his study of Internal medicine.
The Glioma study combines topics in areas such as Isocitrate dehydrogenase and Ependymoma. His Ependymoma study integrates concerns from other disciplines, such as Medulloblastoma and Cohort. His research integrates issues of Cancer, Concordance, Oligodendroglioma and Hazard ratio in his study of Oncology.
Dominique Figarella-Branger spends much of his time researching Pathology, Internal medicine, Cancer research, Glioma and Oncology. His work in Pathology covers topics such as Neural cell adhesion molecule which are related to areas like Cell adhesion molecule. His studies examine the connections between Internal medicine and genetics, as well as such issues in Endocrinology, with regards to Adenoma.
His studies deal with areas such as Carcinogenesis, Cell culture and Immunology as well as Cancer research. His Glioma research integrates issues from Isocitrate dehydrogenase and IDH1. Dominique Figarella-Branger has researched Oncology in several fields, including Cancer and Cohort.
The scientist’s investigation covers issues in Internal medicine, Cancer research, Glioma, Oncology and Pathology. In his study, which falls under the umbrella issue of Internal medicine, Resection is strongly linked to Gastroenterology. Dominique Figarella-Branger interconnects Carcinogenesis, Cancer, Somatic cell, Fusion gene and Mutation in the investigation of issues within Cancer research.
His work carried out in the field of Glioma brings together such families of science as Isocitrate dehydrogenase, Karnofsky Performance Status and IDH1. His Oncology study combines topics in areas such as Medulloblastoma, Regimen, Anaplastic astrocytoma and Glioblastoma. Dominique Figarella-Branger studies Embryonal tumors, a branch of Pathology.
His primary scientific interests are in Cancer research, Glioma, Internal medicine, Oncology and Glioblastoma. He combines subjects such as Cell culture, Progression-free survival, Cell growth, Neuraminidase and Carcinogenesis with his study of Cancer research. He works mostly in the field of Progression-free survival, limiting it down to concerns involving Oncogene Fusion and, occasionally, Solitary fibrous tumor and Survival rate.
Dominique Figarella-Branger has researched Glioma in several fields, including Immunohistochemistry, Ki-67, Isocitrate dehydrogenase and Sanger sequencing. Dominique Figarella-Branger regularly links together related areas like Neurosurgery in his Internal medicine studies. His Grading study, which is part of a larger body of work in Oncology, is frequently linked to In patient, bridging the gap between disciplines.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N. Louis;Arie Perry;Guido Reifenberger;Andreas von Deimling.
Acta Neuropathologica (2016)
International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading
David N. Louis;Arie Perry;Peter Burger;David W. Ellison.
Brain Pathology (2014)
OPA1 mutations induce mitochondrial DNA instability and optic atrophy plus phenotypes
Patrizia Amati-Bonneau;Maria Lucia Valentino;Pascal Reynier;Maria Esther Gallardo.
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs
Dominik Sturm;Dominik Sturm;Brent A. Orr;Umut H. Toprak;Volker Hovestadt.
Central neurocytoma: a synopsis of clinical and histological features.
Jacques Hassoun;Figen Söylemezoglu;Danielle Gambarelli;Dominique Figarella‐Branger.
Brain Pathology (1993)
Macrophagic myofasciitis: an emerging entity
R K Gherardi;M Coquet;P Chérin;F J Authier.
The Lancet (1998)
Pilocytic astrocytomas in children: prognostic factors--a retrospective study of 80 cases.
Carla Fernandez;Dominique Figarella-Branger;Nadine Girard;Corinne Bouvier-Labit.
A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up
Jacqueline Trouillas;Jacqueline Trouillas;Pascal Roy;Nathalie Sturm;Emmanuelle Dantony.
Acta Neuropathologica (2013)
Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis.
Philippe Metellus;Bema Coulibaly;Carole Colin;Carole Colin;Andre Maues de Paula.
Acta Neuropathologica (2010)
Survival and Prognostic Factors of Early Childhood Medulloblastoma: An International Meta-Analysis
Stefan Rutkowski;Katja Von Hoff;Angela Emser;Isabella Zwiener.
Journal of Clinical Oncology (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: